[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356621-105":59,"doc-detail-356621-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-mien1-based-hexamer-peptide-la3ik-inhibits-egf-driven-oncogenic-signaling-in-prostate-cancer-by-disrupting-egfrerbb2-heterodimerization","An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR–ERBB2 heterodimerization","","Advanced prostate cancer is driven in part by Epidermal Growth Factor (EGF) signaling that promotes migration, invasion, and angiogenesis. LA3IK (LAIAVK), a novel MIEN1-based hexapeptide, was evaluated for inhibiting EGF-mediated tumor progression in androgen-independent, EGFR-overexpressing PC3 cells. LA3IK selectively disrupts EGFR–ERBB2 heterodimerization, reduces EGFR phosphorylation (Y1068), suppresses NF-κB, Src, and STAT3 signaling, impairs migration and invasion, and spares proliferation while showing cancer-specific activity and improved safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-mien1-based-hexamer-peptide-la3ik-inhibits-egf-driven-oncogenic-signaling-in-prostate-cancer-by-disrupting-egfrerbb2-heterodimerization/356621/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-mien1-based-hexamer-peptide-la3ik-inhibits-egf-driven-oncogenic-signaling-in-prostate-cancer-by-disrupting-egfrerbb2-heterodimerization/356621.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main mechanism by which LA3IK affects EGF signaling in prostate cancer cells?","Question",{"text":112,"@type":113},"LA3IK selectively disrupts EGFR–ERBB2 heterodimerization, leading to reduced EGFR phosphorylation at Y1068 and suppression of downstream NF-κB, Src, and STAT3 signaling.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What functional outcomes were observed for LA3IK treatment in PC3 prostate cancer cells?",{"text":117,"@type":113},"LA3IK impairs EGF-driven migration and invasion while sparing proliferation, indicating inhibitory effects on malignant behaviors rather than general growth inhibition.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the study address cancer specificity and safety?",{"text":121,"@type":113},"LA3IK inhibits EGF signaling in prostate tumors while preserving physiological EGFR function in healthy liver tissues, supporting a favorable tissue-specific action and safety profile.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356621,1790171423,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAn MIEN1-based hexamer peptide (LA3IK) inhibits EGF-drivenoncogenic signaling in prostate cancer by disrupting EGFR–ERBB2 heterodimerization  \nAmit K. Tripathi1􀀍, Nafees Ahamad1, Antariksh Tyagi2, Benedicta Quainoo3, Adam W. Smith3, Pragati Singh1, Nirupama Sabnis1 & Jamboor K. Vishwanatha1􀀍  \nAdvanced prostate cancer remains challenging, driven in part by Epidermal Growth Factor (EGF) signaling that promotes migration, invasion, and angiogenesis. We evaluated LA3IK (LAIAVK), a novel MIEN1-based hexapeptide, for its ability to inhibit EGF-mediated tumor progression in androgenindependent, EGFR-overexpressing PC3 prostate cancer cells. Our full assessment included mechanistic studies of receptor dimerization, downstream signaling pathways, and functional assays for cancer cell behaviors. The results show that LA3IK selectively disrupts EGFR–ERBB2 heterodimerization, reducing phosphorylation of EGFR atY1068 and downstream signaling through NF-κB, Src, and STAT3 . This leads to impaired EGF-driven migration and invasion while sparing proliferation. Mechanistically, LA3IK induces a tryptophan blue shift in EGF and inhibits EGFR–ERBB2 interaction. Transcriptomic analyses revealed downregulation of angiogenesis-related genesANGPTL4 and VEGFC. Crucially, LA3IK exhibited cancer-specificity, inhibiting EGF signaling in prostate tumors while preserving physiological EGFR function in healthy liver tissues. This tissue-specific action underscores LA3IK’s favorable safety profile. We therefore report LA3IK as the shortest peptide to date that effectively inhibits EGF-mediated tumorigenesis in advanced prostate cancer with minimal off-target effects, highlighting its potential as a precise therapeutic agent.  \nKeywords MIEN1, EGF-mediated cancer progression, EGFR phosphorylation, Migration, Invasion, RNAseq analysis  \nEpidermal Growth Factor (EGF) and its receptor EGFR play pivotal roles in prostate cancer progression and metastasis. In normal prostate tissue, androgens maintain cellular homeostasis by downregulating EGFR expression1. However, this regulatory mechanism is often disrupted in prostate cancer, leading to increased EGFR signaling and subsequent tumor growth, invasion, and metastasis. Enhanced EGFR expression correlates with disease relapses and progression to androgen independence, modulating pathways implicated in proliferation, survival, and invasion, particularly metastasis to bone2. Recent advancements in targeted therapies have highlighted the potential of small molecule inhibitors and peptides to disrupt these aberrant signaling pathways. EGFR inhibitors like gefitinib and erlotinib have shown efficacy in blocking EGFR-mediated signaling, potentially reducing cancer cell proliferation and survival3. In recent years, the development of peptides targeting the EGF and its receptor EGFR has emerged as a promising approach in cancer therapy. Several peptides have been reported to inhibit EGF-EGFR interactions and subsequent signaling pathways. Among these, Disruptin (SVDNPHVC) inhibits EGF-dependent EGFR dimerization by disrupting Hsp90 binding to EGFR4. TE- 64562 (RKKRRQRRRG-RRRHIVRKRTLRRLLQER), a cell-penetrating peptide derived from EGFR residues 645–662 and conjugated to the Tat sequence, has demonstrated the ability to inhibit EGFR dimerization and reduce both phosphorylated and total EGFR levels in various cancer cell types5. GE11 (YHWYGYTPQNVI),  \n1Department of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX, USA.  \n2Yale Center for Genome Analysis (YCGA), Yale School of Medicine, New Haven, CT, USA. 3Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, TX, USA. 􀀍 email: [Amitkumar.tripathi@unthealth.edu](Amitkumar.tripathi@unthealth.edu); [Jamboor.vishwanatha@unthealth.edu](Jamboor.vishwanatha@unthealth.edu)  \na dodecapeptide, binds to EGFR with high affinity and competes with EGF for bin","cbCaia0zuR1HPOaD","https://ap.wps.com/l/cbCaia0zuR1HPOaD","pdf",4054054,17,"English","# Abstract\n## Mechanistic inhibition of EGFR–ERBB2\n## Transcriptomic findings\n## Cancer specificity and safety\n# Background\n## Role of EGF/EGFR in prostate cancer\n## Targeted therapy and peptide approaches\n# Study rationale\n## MIEN1-based peptide LA3IK in prostate cancer\n## Signaling pathways (NF-κB, Src, B-catenin)\n# Materials & methods\n## Antibodies, proteins, drugs, and primers","[{\"question\":\"What is the main mechanism by which LA3IK affects EGF signaling in prostate cancer cells?\",\"answer\":\"LA3IK selectively disrupts EGFR–ERBB2 heterodimerization, leading to reduced EGFR phosphorylation at Y1068 and suppression of downstream NF-κB, Src, and STAT3 signaling.\"},{\"question\":\"What functional outcomes were observed for LA3IK treatment in PC3 prostate cancer cells?\",\"answer\":\"LA3IK impairs EGF-driven migration and invasion while sparing proliferation, indicating inhibitory effects on malignant behaviors rather than general growth inhibition.\"},{\"question\":\"How does the study address cancer specificity and safety?\",\"answer\":\"LA3IK inhibits EGF signaling in prostate tumors while preserving physiological EGFR function in healthy liver tissues, supporting a favorable tissue-specific action and safety profile.\"}]","An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR–ERBB2 heterodimerization | PDF",1790126353,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d1f2fdb9acf69f62bd2ae5c8de1589a.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4eb97fa23ee7769699f4ba77dd060764.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7d4aee97c4e9daff7c488b739ac7d4e.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57e68e3d06d606ccc638111a06154bf0.webp",980,1287]